Biomedical Bonding AB has been granted a patent in China for its novel primer technology
Press release: Biomedical Bonding AB's novel primer formulation has been granted a patent in China. The primer is an enabling technology and part of the Bonevolent™ platform towards strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration treatments.
Biomedical Bonding AB has secured a unique primer formulation patent for use together with its resin-based composite technology, a first of a kind universal fracture fixation solution that is going to be revolutionary in the world of surgery and treatments for fractures. The recently granted patent is now valid in both Europe and China. It would serve essential in BMB's path towards commercialisation.
“We are happy to obtain one additional patent to further strengthen our Bonevolent™ IPR portfolio in key geographical regions. The primer patent family is unique and it protects all key components that collectively enable superior resins-based fixation of bones, metal or teeth. It is a critical component that will allow BMB to pursue its vision towards personalized treatment of both bone fractures fixation as well dental restorations”, says Founder and CEO, Prof. Michael Malkoch.
Biomedical Bonding AB is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.